Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor, ...
Wedbush analyst Laura Chico downgraded Praxis Precision (PRAX) to Underperform from Neutral with a price target of $26, down from $57, after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback